Mirum Pharmaceuticals price target raised to $69 from $64 at JMP Securities

JMP Securities raised the firm’s price target on Mirum Pharmaceuticals to $69 from $64 and keeps an Outperform rating on the shares. Livmarli revenues are in line with Mirum’s preliminary announcement, with management guiding to 2024 net product sales of $310M-$320M, the analyst tells investors in a research note. The next catalyst for shares is the March 13 Prescription Drug User Fee Act data for maralixibat for progressive familial intrahepatic cholestasis, and JMP thinks approval is likely while the 2024 will be “modest,” the firm adds.